Sort   by:  
 Page size 
TranscriptomicsmRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer
The intention was to detect genes that are determining trastuzumab efficiency in HER2-positive breast cancer cell lines with different resistance phenotypes. While BT474 should be sensitive to the drug treatment, HCC1954 is expected to be resistant due to a PI3K mutation. The cell line BTR50 has bee...
ORGANISM(S): Homo sapiens 
2015-04-21 | E-GEOD-55005 | biostudies-arrayexpress
TranscriptomicsTranslational control in early adipogenesis
In obesity, adipose tissue expands by increasing the volume of existing adipocytes (hypertrophy), increasing the number of small adipocytes (hyperplasia) or both. Much is known about transcriptional control during adipogenesis, including early events. However, translational control plays a pivotal r...
ORGANISM(S): Mus musculus 
2012-03-28 | E-GEOD-29744 | biostudies-arrayexpress
TranscriptomicsExtrinsic and Intrinsic Regulation of DOR/TRP53INP2 Expression in Mice
The objective is to relate changes in expression of DOR/TRP53INP2, a factor involved in thyroid hormone action and autophagy, to body composition in mice fed a fat (FD) or high fat diet (HFD) for 8 days and in a genetically obese mouse model. We conclude that DOR expression depends on sex, fat conte...
ORGANISM(S): Mus musculus 
2014-09-30 | E-GEOD-32872 | biostudies-arrayexpress
ProteomicsReverse phase protein array based protein profiling of breast cancer specimens
Expression levels of proteins and phosphoproteins, covering major cancer signaling pathways with a special focus on breast cancer biology, were obtained for a series of 109 breast cancer tumor specimens with positive estrogen receptor status. Tumor specimens from patients diagnosed with primary inva...
ORGANISM(S): Homo sapiens 
2014-02-18 | E-GEOD-47066 | biostudies-arrayexpress
ProteomicsReverse phase protein array based protein profiling of breast cancer specimens (2)
Expression levels of proteins and phosphoproteins, covering major cancer signaling pathways with a special focus on breast cancer biology, were obtained for a series of 164 breast cancer tumor specimens with positive estrogen receptor status. Tumor specimens from patients diagnosed with primary inva...
ORGANISM(S): Homo sapiens 
2014-02-18 | E-GEOD-50861 | biostudies-arrayexpress
Models,MultiomicsHCC1954 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2698 | Cell Collective
Models,MultiomicsBT474 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2699 | Cell Collective
Models,MultiomicsSKBR3 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2703 | Cell Collective
Models,MultiomicsBT474 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2697 | Cell Collective
Models,MultiomicsHCC1954 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2700 | Cell Collective
Sort   by:  
 Page size